BRCA1/2 mutations are responsible for a significant portion of hereditary breast and ovarian cancers. Identifying patients with BRCA1/2 mutations allows for gene-directed surveillance and intervention. The Manchester Scoring System (MSS) is a quick and easy algorithm to identify patients with a likelihood of having a BRCA1/2 mutation. Recently, a third iteration of MSS (MSS3), validated by an European cohort, showed greater sensitivity and specificity over previous MSS models. This Singapore study, showed similar improvements in MMS3 for an ethnically diverse population. Clinicans can use MSS3 to identify patients who may benefit from germline BRCA1/2 testing. (By Mr. Winston Chew, http://jmg.bmj.com/content/early/2017/12/23/jmedgenet-2017-105073 )
